The short answer: for most healthy adults, ashwagandha root extract appears to be well tolerated in short-term use of up to about three months, and long-term safety isn't well established. Some people should avoid it entirely: anyone pregnant or breastfeeding, people with hormone-sensitive prostate cancer, and people with thyroid or autoimmune conditions or upcoming surgery. Rare cases of liver injury have been reported. Denmark banned it in 2023 out of caution; other regulators have chosen warnings instead.
Common side effects
The U.S. National Center for Complementary and Integrative Health lists drowsiness, stomach upset, diarrhea and vomiting as possible side effects (NCCIH). In a 2026 trial of 1,002 adults taking 600 mg a day of KSM-66® root extract for eight weeks, the extract was reported as well tolerated, with laboratory safety markers in normal range; the trial was supplied by the extract's maker.
Who should avoid ashwagandha
| Situation | NCCIH guidance |
|---|---|
| Pregnancy | Avoid |
| Breastfeeding | Should not be used |
| Hormone-sensitive prostate cancer | Avoid (may raise testosterone) |
| Thyroid disorders | Not recommended |
| Autoimmune conditions | Not recommended |
| Upcoming surgery | Not recommended |
Medicines it may interact with
NCCIH lists possible interactions with medicines for diabetes, high blood pressure and thyroid conditions, immunosuppressants, sedatives and anti-seizure medicines. If you take any of these, ask your clinician or pharmacist first.
What about liver injury?
Liver injury linked to ashwagandha supplements is rare, but several cases have been reported. Stop and seek care if you notice yellowing of the skin or eyes, dark urine, itching or unusual fatigue.
Why did Denmark ban ashwagandha?
In 2020, the Technical University of Denmark assessed ashwagandha for the Danish food authority and concluded that the evidence was insufficient to set a safe intake level, citing concerns about effects on sex hormones, the thyroid and pregnancy. Under its precautionary approach, Denmark banned ashwagandha in food supplements in 2023. France's food safety agency advised vulnerable groups to avoid it in 2024, and the Netherlands flagged concerns; the UK's Food Standards Agency said it was not considering a ban. Researchers in India and industry groups have disputed the Danish report, arguing it didn't separate root extracts from leaf. This is a live regulatory debate, not settled science in either direction (NutraIngredients timeline).
Root vs leaf: why it matters
Much of the clinical research uses root extracts. Leaf contains a different profile of compounds, and some regulatory concerns center on leaf use. Look for a product that names a root-only extract and the amount. Calmaura uses 300 mg of organic KSM-66®, a root-only extract (more on KSM-66®).
How to use ashwagandha more safely
- Check the list above, and ask a clinician if anything applies to you.
- Choose a named root extract with a clear amount.
- Don't stack products: count ashwagandha across every supplement.
- Take breaks; most studies ran 8–12 weeks.
- Stop if you notice side effects, especially signs of liver trouble.
Questions people ask
Is ashwagandha safe to take every day?
Short-term daily use (up to three months) may be safe for most healthy adults; long-term safety isn't well established.
Is ashwagandha banned in the US?
No. It's sold as a dietary supplement in the US. Denmark is the only European country to ban it outright as of 2026.
Does ashwagandha affect the thyroid?
It may raise thyroid hormone levels in some people, which is why it isn't recommended with thyroid disorders.
See Calmaura's full label and warnings →
How this article was made
Written by the Calmaura editorial team and checked against the sources below on November 10, 2026. Calmaura sells a product containing ashwagandha, so this is not an independent review; we've tried to present the concerns as fully as the benefits.
- NCCIH: Ashwagandha
- NutraIngredients: regulatory timeline on ashwagandha (2026)
- Patwardhan B, et al. Danish ban on ashwagandha: truth, evidence, ethics, and regulations (2024)
- Nutritional Outlook: 1,002-participant KSM-66® safety trial
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is general information, not individual medical advice.